The development of PARP inhibitors in ovarian cancer: from bench to bedside

por Drew, Yvette
Publicado 2015

Tipping Growth Inhibition into Apoptosis by Combining Treatment with MDM2 and WIP1 Inhibitors in p53(WT) Uterine Leiomyosarcoma

por Chamberlain, Victoria, Drew, Yvette, Lunec, John
Publicado 2021

Targeting the ATR-CHK1 Axis in Cancer Therapy

por Rundle, Stuart, Bradbury, Alice, Drew, Yvette, Curtin, Nicola J.
Publicado 2017

Emerging treatment options for ovarian cancer: focus on rucaparib

por Mariappan, Lavanya, Jiang, Xue Yan, Jackson, Josie, Drew, Yvette
Publicado 2017

The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response

por Bradbury, Alice, Zenke, Frank T., Curtin, Nicola J., Drew, Yvette
Publicado 2022

Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling

por Smith, Hannah L., Willmore, Elaine, Mukhopadhyay, Asima, Drew, Yvette, Curtin, Nicola J.
Publicado 2022

Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeti...

por Bradbury, Alice, O’Donnell, Rachel, Drew, Yvette, Curtin, Nicola J., Sharma Saha, Sweta
Publicado 2020

Real‐World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10

por Drew, Yvette, Kristeleit, Rebecca S., Oaknin, Ana, Ray‐Coquard, Isabelle, Haris, Noor Md., Swisher, Elizabeth M.
Publicado 2019

Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer

por Sharma Saha, Sweta, Gentles, Lucy, Bradbury, Alice, Brecht, Dominik, Robinson, Rebecca, O’Donnell, Rachel, Curtin, Nicola J., Drew, Yvette
Publicado 2021

Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types

por Gentles, Lucy, Goranov, Bojidar, Matheson, Elizabeth, Herriott, Ashleigh, Kaufmann, Angelika, Hall, Sally, Mukhopadhyay, Asima, Drew, Yvette, Curtin, Nicola J., O’Donnell, Rachel L
Publicado 2019

Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment

por Grechko, Nikolay, Skarbova, Viera, Tomaszewska-Kiecana, Monika, Ramlau, Rodryg, Centkowski, Piotr, Drew, Yvette, Dziadziuszko, Rafal, Zemanova, Milada, Beltman, Jeri, Nash, Eileen, Habeck, Jenn, Liao, Mingxiang, Xiao, Jim
Publicado 2021

Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor

por Franklin, Miriam, Gentles, Lucy, Matheson, Elizabeth, Bown, Nick, Cross, Paul, Ralte, Angela, Gilkes‐Immeson, Connor, Bradbury, Alice, Zanjirband, Maryam, Lunec, John, Drew, Yvette, O'Donnell, Rachel, Curtin, Nicola J.
Publicado 2018

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors

por Shapiro, Geoffrey I., Kristeleit, Rebecca S., Burris, Howard A., LoRusso, Patricia, Patel, Manish R., Drew, Yvette, Giordano, Heidi, Maloney, Lara, Watkins, Simon, Goble, Sandra, Jaw‐Tsai, Sarah, Xiao, Jim J.
Publicado 2018

First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor

por Plummer, Ruth, Dua, Divyanshu, Cresti, Nicola, Drew, Yvette, Stephens, Peter, Foegh, Marie, Knudsen, Steen, Sachdev, Pallavi, Mistry, Bipin M., Dixit, Vaishali, McGonigle, Sharon, Hall, Nancy, Matijevic, Mark, McGrath, Shannon, Sarker, Debashis
Publicado 2020

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with...

por Drew, Yvette, Ledermann, Jonathan, Hall, Geoff, Rea, Daniel, Glasspool, Ros, Highley, Martin, Jayson, Gordon, Sludden, Julieann, Murray, James, Jamieson, David, Halford, Sarah, Acton, Gary, Backholer, Zoe, Mangano, Raffaella, Boddy, Alan, Curtin, Nicola, Plummer, Ruth
Publicado 2016

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with...

por Drew, Yvette, Ledermann, Jonathan, Hall, Geoff, Rea, Daniel, Glasspool, Ros, Highley, Martin, Jayson, Gordon, Sludden, Julieann, Murray, James, Jamieson, David, Halford, Sarah, Acton, Gary, Backholer, Zoe, Mangano, Raffaella, Boddy, Alan, Curtin, Nicola, Plummer, Ruth
Publicado 2016

A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and oth...

por El Helali, Aya, Plummer, Ruth, Jayson, Gordon C., Coyle, Vicky M., Drew, Yvette, Mescallado, Nerissa, Harris, Noor, Clamp, Andrew R., McCann, Janine, Swaisland, Helen, Kennedy, Richard D., Cranston, Aaron N., Wilson, Richard H.
Publicado 2022